Mar 14, 2018 7:00am EDT Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference
Mar 06, 2018 7:00am EST Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference
Feb 28, 2018 9:25am EST Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
Feb 22, 2018 8:00am EST Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
Feb 12, 2018 7:00am EST Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
Jan 25, 2018 7:00am EST Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
